세계의 심장 펌프 기기 시장 규모는 2023년에 27억 3,000만 달러, 2030년까지 63억 5,000만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 15.16%의 성장이 전망됩니다. 심장 펌프 기기의 수요는 주로 심혈관질환(CVD)의 유병률 증가, 노년 인구의 증가, 파이프라인 단계에 있는 제품을 가진 다양한 기업에 의해 촉진되고 있습니다. 심장 펌프 기기는 COVID-19의 심부전 사례에서 매우 유익한 것으로 판명되어 대유행 상황에서 이러한 장비에 대한 수요를 더욱 증가 시켰습니다. 심장 공급업체가 부족하기 때문에 심장 펌프는 세계 시장 확대를 촉진하는 최적의 솔루션이 되고 있습니다. 그럼에도 불구하고, 펌프의 높은 비용과 개발도상국 시장의 낮은 이익률 시나리오와 같은 요인은 시장 성장을 억제할 것으로 예상됩니다.
심장 펌프 기기 시장 역학
미국심장협회(American Heart Association)(2022)에 따르면 2020년 전 세계에서 약 2억 4,410만 명이 관상동맥(허혈성) 심장질환을 앓고 있다고 합니다.
British Heart Foundation(2022)의 자료에 따르면 2019년 전 세계에서 약 5억 5,000만 명, 즉 14명 중 1명이 심장 및 순환기 질환을 앓고 있으며, 여기에는 약 2억 9,000만 명의 여성과 약 2억 6,000만 명의 남성이 포함됩니다.
위 자료는 또한 관상동맥(허혈성) 심장질환, 말초동맥(혈관) 질환, 뇌졸중, 심방세동이 2019년 세계에서 가장 흔하고 유병률이 높은 심혈관 질환으로 꼽혔습니다.
세계보건기구(PAHO)(2022)에 따르면 심혈관 질환은 다른 어떤 질병보다 연간 사망자 수가 많습니다. 심장병과 뇌졸중으로 인한 사망은 2021년 중저소득 국가 전체 사망자의 4분의 3 이상을 차지합니다.
심장 펌프 기기에 대한 연구개발 활동 증가는 심장 펌프 기기 시장의 성장을 더욱 촉진할 것입니다. 예를 들어 2022년 8월 Abbott는 MOMENTUM 3 시험에서 얻은 데이터를 바탕으로 자사의 HeartMate 3 심장 펌프가 심부전 환자의 생존 기간을 최소 5년 이상 연장할 수 있다고 발표했습니다.
따라서 앞서 언급한 요인들은 향후 수년간 전체 심장 펌프 기기 시장을 끌어올릴 것으로 예상됩니다.
그러나 펌프의 높은 비용과 개발도상국의 저매출 시나리오는 심장 펌프 기기 시장의 성장을 저해하는 요인으로 작용할 수 있습니다.
심장 펌프 기기 시장 부문 분석
심장 펌프 기기 시장의 제품 부문에서 심실보조장치(VAD) 카테고리에 속하는 좌심실 심실보조장치(VAD)(LVAD)이 가장 큰 비중을 차지할 것으로 예상되며, 이는 시장에서 가장 빠르게 성장하는 부문 중 하나입니다.
이는 주로 LVAD와 관련된 장점과 용도 외에도 기술 발전, 장기 기증자 부족, 전 세계 심부전 유병률 증가에 기인합니다.
LVAD는 정상적인 혈류를 회복시켜 중증 심부전 환자를 치료하는 것을 목적으로 합니다. 심부전 환자에게 LVAD를 이식하면 생명을 구하고 장기 이식까지 시간을 벌 수 있습니다.
LVAD는 신뢰성이 높고 안전 시스템이 내장되어 있습니다.
LVAD를 이식한 후 환자는 건강 상태가 개선되어 운동 및 기타 일상 활동으로 복귀/재개할 수 있습니다.
LVAD는 중증 심부전 환자에게 중장기적인 치료 솔루션을 제공합니다.
따라서 위의 모든 요인들이 심장 펌프 기기 시장의 성장을 가속할 것으로 예상됩니다.
북미가 전체 심장 펌프 기기 시장을 독점할 것으로 예상됩니다.
예측 기간 중 북미가 전체 심장 펌프 기기 시장을 장악할 것으로 예상됩니다. 이는 심혈관 질환(CVD) 환자 인구가 많고, 제품 개발 및 시장 개발에 있으며, 매우 강력한 시장이며, 높은 소비자 인지도와 지역내 주요 시장 기업의 존재가 시장 성장을 가속하고 있기 때문으로 분석됩니다.
세계의 심장 펌프 기기 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
Heart Pump Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of cardiovascular diseases (CVDs) and increasing research and development activities
The global heart pump devices market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030. The demand for heart pump devices is primarily motivated by the increase in cardiovascular disease (CVDs) prevalence, the rise in the geriatric population, and various companies with products in their pipeline phase. Heart Pump devices were found to be extremely beneficial in heart failure cases in COVID-19 which further pushed for the demand for these devices during the pandemic situation. Due to a scarcity of heart suppliers, cardiac pumps are an optimal solution that encourages Global market expansion. Factors such as the high cost of the pump and a low repayment scenario in developing countries are nevertheless projected to inhibit the growth of the market.
Heart Pump Devices Market Dynamics:
According to the American Heart Association 2022, about 244.1 million people were globally living with coronary (ischemic) heart disease in 2020.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
According to Pan American Health Organization (PAHO) 2022, cardiovascular diseases cause more deaths yearly than any other disease. Heart disease and stroke-related fatalities account for more than three-quarters of all deaths in low- and middle-income nations in 2021.
The increasing number of research and development activities pertaining to heart pump devices is further going to assist in the growth of the heart pump devices market. For example, in August 2022, Abbott based upon data obtained from the MOMENTUM 3 trial announced that its HeartMate 3 heart pump extends the survival of heart failure patients by at least five years.
Therefore, the afore-said factor will propel the overall market of heart pump devices in the upcoming years.
However, the high cost of the pump and low repayment scenario in developing countries may act as a restraint in the growth of the heart pump devices market.
Heart Pump Devices Market Segment Analysis:
Heart Pump Devices by Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the heart pump devices market, left ventricular assist devices (LVAD) under the ventricular assist devices category are expected to hold the largest share and are one of the fastest-growing segments in this market.
It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.
LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.
LVADs are highly reliable and come with built-in safety systems.
Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.
LVADs offer intermediate to long-term treatment solutions for severe heart failure patients.
Hence, all the above-mentioned factors are expected to drive the segment growth of the heart pump devices market.
North America is expected to dominate the overall Heart Pump Devices Market:
North America is expected to dominate the overall Heart Pump Devices market during the forecast period. This can be ascribed to the presence of a large patient pool suffering from cardiovascular diseases (CVDs), the highly potent market in terms of product development and launches, high consumer awareness, and the presence of local key market players among other factors in the country, driving the market growth.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.
Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
The increasing number of product development activities in the region is further going to accelerate the growth of the heart pump devices market. For example, in August 2021, the US Food and Drug Administration granted a breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
Thus, due to the increase in demand for heart pump devices in the region, there will be a subsequent rise in the growth of heart pump devices regional market during the forecast period.
Heart Pump Devices Market Companies:
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
Recent Developmental Activities in the Heart Pump Devices Market:
In August 2021, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous Heart Pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
In February 2021, CARMAT received FDA approval to conduct an Early Feasibility Study (EFS) of its Total Artificial Heart in the US using BlueSync technology.
In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.
Key Takeaways from the Heart Pump Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Heart Pump Devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Global Heart Pump Devices Market.
Various opportunities are available for the other competitor in the Heart Pump Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Heart Pump Devices market growth in the coming future?
Target Audience who can be benefited from This Heart Pump Devices Market Report Study
Heart Pump Devices providers
Research organizations and consulting companies
Heart Pump Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Heart Pump Devices
Various End-users want to know more about the Heart Pump Devices Market and the latest technological developments in the Heart Pump Devices market.
Frequently Asked Questions for the Heart Pump Devices Market:
What are Heart Pump Devices?
Heart pump devices are utilized in patients that are suffering from heart issues such as a recent cardiac arrest. They carry out the normal functions of the heart by maintaining regular cardiac circulation and replacing the heart partially or completely. After receiving the blood from the heart's lower chambers, it helps transfer the blood to all the vital organs in the body.
What is the market for Global Heart Pump Devices?
Global Heart Pump Devices Market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030.
What are the drivers for Global Heart Pump Devices?
The major drivers driving the demand for Heart Pump Devices are the increasing prevalence of cardiovascular diseases, the rising geriatric population, and new product development by the market players.
What are the key players operating in Global Heart Pump Devices?
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
What regions have the highest share in the Heart Pump Devices market?
North America is expected to dominate the overall Heart Pump Devices market during the forecast period, 2024 to 2030. This domination is due to the growing demand for advanced technologies in Heart Pump Devices, the increasing chronic disease in the region is driving the regional growth.